Mongolia vs Mozambique: Average cost of multi drug-resistant tuberculosis treatment
Mongolia
1,500 constant 2022 US$
in 2024
Mozambique
1,250 constant 2022 US$
in 2024
Mongolia rank
34th
Mozambique rank
37th
Average cost of multi drug-resistant tuberculosis treatment over time
- Mongolia
- Mozambique
How they compare
Mongolia currently reports 1,500 constant 2022 US$ against 1,250 constant 2022 US$ in Mozambique, a difference of 250 constant 2022 US$.
That makes Mongolia's figure about 1.2 times Mozambique's.
The two have swapped places 1 time across 8 shared years of data; in 2017 it was Mozambique ahead.
Mongolia ranks 34th and Mozambique ranks 37th of 92 countries.
Mozambique has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Mongolia | Mozambique | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,573 constant 2022 US$ | 3,095 constant 2022 US$ | 521.67 constant 2022 US$ | Mozambique |
| 2020s | 1,455 constant 2022 US$ | 2,464 constant 2022 US$ | 1,009 constant 2022 US$ | Mozambique |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Mongolia or Mozambique?
- Mongolia, at 1,500 constant 2022 US$ against 1,250 constant 2022 US$ in Mozambique as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Mongolia and Mozambique?
- 250 constant 2022 US$, with Mongolia ahead.
- How many years of comparable data are there for Mongolia and Mozambique?
- 8 years are reported by both, from 2017 to 2024.
- How do Mongolia and Mozambique rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Mongolia ranks 34th and Mozambique ranks 37th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.